Beyond the Headline Number: Deal Structures That Determine What HealthTech, MedTech, Healthcare AI, Health IT, Digital Health Founders Actually Take Home

Nelson Advisors
56 minutes ago
14 min read

In lower to upper mid-market mergers and acquisitions, specifically within the €25M to €250M enterprise value (EV) corridor, the headline purchase price is frequently a vanity metric. While boardrooms, press releases, and founder networks celebrate the headline valuation, the actual net economic proceeds delivered to selling shareholders at closing (and across post-closing settlement periods) are governed by a complex matrix of legal risk allocation, working capital mechanics, deferred consideration instruments, and structural retentions.

The gap between headline enterprise value and net founder realisation is where corporate finance advisors, private equity sponsors and strategic acquirers negotiate for structural advantage. A deal structured with an aggressive headline EV can easily net a founder significantly less cash, with vastly higher tail risk, than a lower headline offer structured with clean completion mechanics, robust insurance coverage, and minimal contingent holdbacks.

The Anomaly of Enterprise Value: Deconstructing the Proceeds Gap

Enterprise Value represents the theoretical operating value of a business on a cash-free, debt-free basis, assuming a standardised level of net working capital. However, converting Enterprise Value into Equity Value and subsequently into liquid cash distributed to founders, requires navigating multiple mathematical and structural subtractions.

Equity Value = Enterprise Value - Funded Debt + Cash - Working Capital Adjustment

Net Cash at Closing = Equity Value - Rollover Equity - Contingent Earn Outs - Indemnity Escrows - Transaction Feea

Beyond standard balance sheet financial adjustments (such as deducting third-party bank debt and adding back free cash), acquirers deploy deal structuring mechanisms that shift operational volatility and future earnings risk onto the seller. These mechanism fall into three structural categories:

Timing and Pricing Mechanics: Selection between completion accounts and locked box mechanisms dictates whether economic volatility and earnings generated between signing and closing accrue to the founder or the acquirer.
Deferred Consideration Structures: Earn-outs, milestone holdbacks, and vendor notes defer cash outflows for the buyer while creating severe operational and legal dependencies for the founder post-closing.
Liability Retention Architecture: Indemnity escrows, Warranty & Indemnity (W&I) insurance deductibles and purchase price adjustment true-ups expose founders to multi-year post-closing financial exposure.

Understanding how these levers operate across European mid-market transactions is vital for founders seeking to maximise post-tax liquid proceeds while eliminating post-closing liabilities.

Price Determination Mechanics: Locked Box versus Completion Accounts

The legal mechanism selected to establish the final purchase price determines whether value created during the period between the valuation reference date and transaction completion transfers to the buyer or remains with the seller. In European mid-market private M&A, the market is divided between Locked Box mechanisms and Completion Accounts true-ups.

Under a locked box structure, the purchase price is fixed using a historical, audited balance sheet at a designated locked box date prior to signing. Economic risk and benefit pass to the buyer as of that historical reference date. To prevent founders from extracting value before completion, the Sale and Purchase Agreement (SPA) contains covenants prohibiting unpermitted leakage.

Unpermitted leakage encompasses non-arm's-length distributions to selling shareholders, such as extraordinary dividends, advisory fee reimbursements, management bonuses, or asset transfers, triggering euro-for-euro indemnity clawbacks. Permitted leakage covers agreed operational expenses, director salaries, or intra-group charges explicitly factored into the purchase price equity bridge. Because sellers continue running the business on behalf of the buyer from the locked box date to completion, sellers routinely negotiate a value ticker—a daily interest rate (typically 3% to 6% per annum) applied to the purchase price over the intervening period to compensate for delayed cash receipt.

Conversely, completion accounts mechanisms adjust the purchase price post-closing based on a balance sheet drawn up as of the completion date, typically prepared by the buyer within 60 to 120 days post-closing. The purchase price fluctuates euro-for-euro based on actual debt, actual cash, and the variance between actual Net Working Capital (NWC) and an agreed Working Capital Peg.

Completion accounts create risk for founders due to potential accounting policy arbitrage, where buyers apply conservative bad-debt provisions or inventory write downs to depress the final balance sheet value. Furthermore, fast-growing companies requiring expanding operational capital can suffer purchase price reductions if the target working capital peg is set artificially high.

According to transaction data from the CMS European M&A Study, locked box adoption in non-purchase price adjustment transactions rose to 60% in 2024, exceeding its ten-year historical average of 55%. In European Private Equity buyouts, locked box mechanics represent the primary market standard, deployed in 82% of transactions. PE sponsors favor locked box structures because they offer absolute pricing certainty and enable an immediate, clean distribution of capital to Limited Partners without exposure to post-closing accounting disputes.

Structural Dimension	Locked Box Mechanism	Completion Accounts Mechanism
Pricing Certainty Date	Fixed at a historical balance sheet date prior to signing.	Variable; established 60 to 120 days post-closing via true-up accounts.
Economic Risk Transfer	Transfers to buyer on the historical Locked Box Date.	Transfers to buyer on the Closing Date.
Pre-Closing Value Accretion	Retained by seller via a negotiated value ticker/interest rate.	Captured within closing balance sheet cash and working capital metrics.
European Market Adoption	60% in non-PPA M&A; 82% in PE Buyout transactions.	~40% in general M&A; standard in US cross-border transactions.
Post-Closing Dispute Exposure	Low; restricted to Unpermitted Leakage indemnity claims.	High; vulnerable to accounting policy disputes and NWC peg true-ups.

Contractual Risk Allocation: Escrows, W&I Insurance and Liability Architecture

The risk allocation architecture within a Sale and Purchase Agreement defines how much of the headline purchase price remains exposed to post-closing indemnification claims for breaches of seller representations and warranties.

Warranty & Indemnity (W&I) insurance has altered European private M&A risk allocation by shifting operational warranty risks onto institutional insurance underwriters. In a standard buy-side W&I transaction, the buyer enters into an insurance policy that pays out directly for financial losses caused by breaches of target warranties. This enables sellers to negotiate a clean exit or synthetic warranty structure where maximum aggregate legal liability under the SPA is capped at a nominal amount, frequently €1 or 0.5% of the purchase price, effectively representing the policy retention deductible.

W&I coverage is subject to specific exclusions. Standard policies exclude known matters disclosed during due diligence, forward-looking financial performance, specific tax liabilities, environmental liabilities, and pension shortfalls. Uninsured exposures must be backed by specific direct seller indemnities or standalone escrow holdbacks.

Data from the CMS European M&A Study and CMS Private Equity Study demonstrates a strong correlation between transaction enterprise value and W&I insurance penetration across European deals.

Deal Size Tier (Enterprise Value)	Private Equity Buyout W&I Penetration	General European M&A W&I Penetration	Primary Economic and Structural Drivers
Under €25M EV	19%	~5% – 10%	Premium cost floors (€40k–€70k minimums) limit economic feasibility.
€25M to €100M EV	58%	~38%	Standard mid-market risk mitigation; efficient premium-to-value scaling.
Over €100M EV	83%	~47% – 52%	Institutional PE exit requirement; competitive auction dynamic driver.

In transactions executed without W&I insurance, buyers rely on direct cash escrows and liability limitations to hedge operational risk:

Indemnity Cash Escrows: A portion of the headline purchase price (typically 5% to 15%) is withheld at closing and locked in a third-party escrow account for 12 to 24 months to secure warranty claims.
General Liability Caps: In non-insured deals, liability caps for general operational warranties typically range between 20% and 50% of the purchase price, whereas deals exceeding €100M EV frequently feature caps below 10%.
De Minimis and Deductible Basket Thresholds: Individual claims below a de minimis threshold (commonly 0.1% to 0.25% of purchase price) are disregarded. Aggregate claims must exceed a threshold (basket) before becoming actionable. In an excess-only basket, the seller is liable only for amounts exceeding the basket; in a first-dollar (tipping) basket, the seller becomes liable for all claims from the first euro once the threshold is breached.
Limitation Periods: General operational warranty limitation periods across Europe typically span 12 to 24 months, whereas tax, fundamental title, and environmental warranties extend from 5 to 7 years.

Earn Outs in HealthTech: Milestones, Operational Covenants and Judicial Standards

In high-growth sectors such as HealthTech, MedTech and digital health, valuation expectations between founders and acquirers frequently diverge. Founders price targets on the future addressable market of unapproved medical devices, regulatory clearances, or unscaled SaaS subscriptions; acquirers price the risk of regulatory delays, adoption friction, and operational integration challenges. To bridge this valuation gap, deal structures incorporate contingent earn outs, which historically comprise between 22% and 28% of total transaction consideration across market cycles.

Surveys of institutional M&A market participants indicate that 92% of investors view bridging valuation gaps as a primary driver for earn-out integration, while 81.6% highlight protection against overpayment. Earn-outs featured in 25% of all European transactions in 2024. However, in HealthTech deals, earn-outs present structural risks for founders, who relinquish operational control while remaining financially exposed to post-closing performance targets.

HealthTech earn-out milestones split into non-financial clinical/regulatory targets and post-closing financial performance metrics:

Clinical and Regulatory Milestones: Common in early-to-mid-stage HealthTech targets. Payout triggers are tied to binary operational events, such as completing Phase III clinical trials, securing US FDA 510(k) or Premarket Approval (PMA), achieving European Union Medical Device Regulation (EU MDR) CE-mark certification, or obtaining specific reimbursement codes (e.g., CPT codes in the US or DiGA list inclusions in Germany). Binary regulatory milestones eliminate accounting disputes but expose founders to regulatory timeline delays beyond their control.
Financial Performance Metrics: According to the CMS European M&A Study, among financial earn-outs, EBIT/EBITDA-based metrics rebounded to 47% of earn-out structures in 2024 (up from 36% in 2023), while Revenue/Turnover-based metrics comprised 26%. Founders prefer revenue-based metrics because they prevent acquirers from artificially depressing post-closing margins through central corporate overhead allocations. Acquirers favour EBITDA targets to guarantee profitable growth, creating potential friction over post-closing cost structures.

Post-closing disputes frequently center on whether an acquirer diluted, starved, or redirected the acquired business, frustrating the earn-out. When evaluating "Commercially Reasonable Efforts" (CRE) clauses, courts scrutinize specific contractual definitions to determine acquirer obligations. Recent rulings from the Delaware Court of Chancery highlight the critical role of CRE clause construction:

In Shareholder Representative Services (SRS) v. Alexion Pharmaceuticals, the merger agreement defined CRE based on an objective, outward-facing standard benchmarked against typical efforts used by biopharmaceutical companies of similar size and scope for similar products. The court ruled that Alexion could not consider its own internal corporate initiatives ("10 by 2023") or post-merger synergy goals when deciding to discontinue the target's drug candidate, finding the buyer liable for breaching its efforts obligation.

Conversely, in Himawan v. Cephalon, the CRE clause was defined using a subjective, inward-facing standard benchmarked against a company with "substantially the same resources and expertise as Cephalon, with due regard to the nature of efforts and cost required". The court held that the phrase "due regard to... costs required" allowed the acquirer to evaluate its own self-interest, opportunity costs, and expected milestone payments, rendering its decision to cease development legally permissible despite eliminating the founder's earn-out.

In Fortis Advisors v. Medtronic Minimed, Medtronic acquired Companion Medical under a structure featuring $100M in contingent milestones. The agreement granted Medtronic operational discretion, subject to a covenant that it would not act for the primary purpose of frustrating the milestone payment. The Delaware Chancery Court dismissed the seller's claim, ruling that even if Medtronic's operational restructuring hindered product sales, the seller failed to prove that milestone frustration was Medtronic's primary subjective intent.

Finally, in SRS v. Johnson & Johnson (Auris Health), J&J was ordered to pay $1B in damages after the court found it breached an inward-facing CRE covenant by forcing an acquired robotic surgery target into an internal competition against a competing internal J&J platform, cannibalizing technical resources and undermining agreed regulatory paths.

Structural Dimension	Outward-Facing (Objective) CRE Standard	Inward-Facing (Subjective) CRE Standard
Reference Benchmark	Industry peers of similar size, scope, and resource capitalization.	The specific acquirer's historic internal practices and priorities.
Internal Cost & Synergy Inclusion	Excluded; acquirer cannot alter efforts based on internal cost cuts.	Permitted; acquirer may factor in opportunity costs and ROI hurdles.
Legal Protection for Sellers	High; prevents acquirer from prioritizing internal corporate initiatives.	Low; protects acquirer operational decisions taken in its self-interest.
Key Judicial Precedents	SRS v. Alexion Pharmaceuticals (Del. Ch. 2024).	Himawan v. Cephalon (Del. Ch. 2024); Fortis v. Medtronic.

To protect contingent value in HealthTech transactions, founders must negotiate four specific structural safeguards:

Mandatory Minimum R&D Budgets: Binding, multi-year R&D and operational funding commitments attached directly to the Sale and Purchase Agreement as an irrevocable schedule.
Key Personnel Operational Autonomy: Covenants requiring key technical and clinical executives to retain operational leadership over the target asset post-closing.
Anti-Cannibalisation Covenants: Restrictions prohibiting the buyer from acquiring, developing, or prioritising competing internal products during the earn-out period.
Deemed Achievement Triggers: Provisions stipulating that if the buyer breaches operational covenants, abandons development, or restructures the target division without consent, all contingent earn-out payments are immediately accelerated and payable in full.

Rollover Equity in Private Equity: Evaluating the "Second Bite at the Apple"

When a Private Equity sponsor acquires a mid-market enterprise (€25M–€250M EV), they rarely purchase 100% of the target equity for cash. Instead, sponsors require selling founders to reinvest ("rollover") between 10% and 40% of their net proceeds alongside the sponsor into a newly formed holding entity (NewCo).

While presented as an opportunity to secure a "second bite at the apple" upon NewCo's eventual exit, rollover equity is subject to structural dilution, leverage dynamics, and capital waterfall subordination that can erode its ultimate economic value.

Capital Waterfall Subordination Metrics

PE sponsors frequently implement strip financing or issue preferred equity instruments to their own fund entities rather than holding standard common equity:

The sponsor funds a substantial portion of its equity check via Preferred Shares carrying an 8% to 10% annual cumulative dividend hurdle.
The founder's rollover capital is invested into Common Shares positioned below the preferred return layer in the capital waterfall.
In a modest or flat secondary exit, accumulated preferred dividends consume the available equity value pool,reducing common rollover equity value even if the business maintains its entry valuation.

Additionally, NewCo platforms establish Management Incentive Plan (MIP) option pools comprising 10% to 15% of total equity to recruit incoming executive leadership. If this MIP pool is carved out exclusively from the common equity tranche post-closing, the founder's relative percentage ownership suffers immediate dilution.

Mid-market PE sponsors also apply leverage (3.0x to 5.0x EBITDA) to fund the initial acquisition. High debt loads increase fixed interest obligations, diverting operational cash flow away from scaling initiatives toward debt service. Furthermore, if NewCo requires follow-on capital for buy-and-build acquisitions and the founder lacks liquidity to participate pro-rata, the sponsor can issue down-round capital calls, diluting the founder's equity ownership percentage.

Priority Layer	Instrument / Equity Class	Capital Waterfall Distribution Mechanics	Impact on Founder Rollover Value
Layer 1: Senior Debt	Third-Party Bank Debt / Unitranche	Full principal and accrued interest paid off first at exit.	Reduces equity value available for distribution.
Layer 2: Preferred Equity	Sponsor Preferred Shares	Receives 100% capital return plus 8%–10% cumulative dividend hurdle.	Subordinates common equity; absorbs capital pool in flat exits.
Layer 3: Option Pool	Management Incentive Plan (MIP)	Dilutes 10%–15% of equity to reward new key executives.	Carved out post-closing; dilutes common equity holders.
Layer 4: Common Equity	Founder Rollover & Sponsor Common	Shares remaining proceeds pro-rata based on common ownership %.	Highly volatile; dependent on growth exceeding preferred hurdles.

Comprehensive Financial Analysis: A €100M Enterprise Value Worked Example

To illustrate how legal and pricing mechanics impact liquid cash realisation, consider two competing acquisition offers for HealthDigital GmbH, a hypothetical European HealthTech company generating €15.0M in EBITDA.

Baseline Business Financials

Headline Enterprise Value Offered: €100.0M (6.67x EBITDA)
Third-Party Funded Debt: €10.0M
Balance Sheet Cash: €2.0M
Agreed Target Net Working Capital (Peg): €5.0M
Actual Net Working Capital at Close: €3.5M (Deficit: €1.5M)
Transaction Advisory Expenses: €3.0M
Founder Ownership: 100%

Offer Structure Comparison

Offer A: Financial Sponsor Buyout Offer

Price Mechanism: Completion Accounts adjustment; high leverage.
Consideration Breakdown: 50% Upfront Cash (€50M), 30% Rollover Equity (€30M) into NewCo common equity subordinated to preferred hurdles, 20% Contingent Earn-out (€20M).
Earn-Out Terms: Tied to achieving aggressive 25% YoY EBITDA growth over 3 years under an inward-facing CRE clause granting buyer operational discretion.
Risk Retainage: 10% Cash Escrow withheld for 24 months (€5.0M); no W&I insurance utilized.
Working Capital Adjustment: Deducts €1.5M post-closing deficit below target peg.

Offer B: Strategic Acquirer Trade Sale Offer

Price Mechanism: Locked Box mechanism with value ticker (4% per annum for 6-month period between signing and closing = +€2.0M).
Consideration Breakdown: 95% Upfront Cash (€95M), 5% Regulatory Milestone Earn-out (€5M).
Earn-Out Terms: Tied to an objective FDA 510(k) submission milestone backed by guaranteed R&D budget covenants.
Risk Retainage: Buy-side W&I policy deployed; SPA liability capped at €100k; zero cash escrow. Founder pays €300k share of W&I premium.
Working Capital Adjustment: None (Locked Box structure; delivered working capital accepted within agreed parameters).

Detailed Purchase Price and Proceeds Waterfall

Waterfall Line-Item	Offer A: Financial Sponsor (PE Rollover + Earn-Out)	Offer B: Strategic Acquirer (Locked Box + W&I)	Strategic Variance / Net Proceeds Delta
Headline Enterprise Value	€100,000,000	€100,000,000	€0
(-) Debt Payoff Deduction	(€10,000,000)	(€10,000,000)	€0
(+) Cash Add-Back	€2,000,000	€2,000,000	€0
(+) Value Ticker / Interest Accretion	€0 (Completion Accounts)	€2,000,000 (4% p.a. over 6 mos)	+€2,000,000
(-) Net Working Capital Deficit	(€1,500,000) (Post-close deduction)	€0 (Locked Box Protection)	+€1,500,000
Calculated Equity Value	€90,500,000	€94,000,000	+€3,500,000
(-) Rollover Equity Requirement	(€30,000,000)	€0	+€30,000,000
(-) Contingent Earn-Out Holdback	(€20,000,000)	(€5,000,000)	+€15,000,000
(-) Indemnity Cash Escrow	(€5,000,000) (Locked 24 months)	€0 (Zero Escrow via W&I)	+€5,000,000
(-) W&I Insurance Premium Share	€0	(€300,000)	(€300,000)
(-) M&A Transaction Advisory Fees	(€3,000,000)	(€3,000,000)	€0
NET CASH IN HAND AT CLOSING	€32,500,000	€85,700,000	+€53,200,000

Despite identical €100M headline enterprise values, Offer B delivers €85.7M in cash at closing, compared to €32.5M under Offer A, creating an immediate €53.2M (163%) upfront liquidity gap.

To evaluate total net economic realisation across a 3-year post-closing horizon, probability weighting must be applied to non-cash and contingent offer components:

3-Year Proceeds Horizon Component	Offer A Expected Realisation Value	Offer B Expected Realisation Value	Underlying Risk & Valuation Explanations
Upfront Cash at Closing	€32,500,000 (100% Probability)	€85,700,000 (100% Probability)	Certain liquid cash received at transaction completion.
Escrow Cash Release	€2,500,000 (50% Probability Weighting)	€0 (No Escrow Required)	Offer A escrow exposed to completion account disputes and claims.
Contingent Earn-Out Realization	€4,000,000 (20% Probability Weighting)	€4,250,000 (85% Probability Weighting)	Offer A target vulnerable under inward CRE; Offer B backed by budget covenants.
Rollover Equity Exit Value	€15,000,000 (50% Realization Weighting)	€0 (No Rollover Required)	Offer A common equity subordinated to debt and sponsor preferred hurdles.
TOTAL 3-YEAR EXPECTED REALISATION	€54,000,000	€89,950,000	Offer B delivers €35.95M (+66.6%) higher risk-adjusted cash proceeds.

Strategic Conclusions and Execution Roadmap for Founders

The quantitative variance between Offer A and Offer B demonstrates that deal terms dictate true financial outcomes. Headline enterprise value serves merely as an initial reference point; actual proceeds depend on the legal and structural provisions negotiated within the Sale and Purchase Agreement.

To optimise cash realisation and eliminate post-closing tail risk, founders preparing for an exit within the €25M to €250M enterprise value corridor should adopt four strategic rules:

Prioritise Locked Box Pricing Mechanisms: Deploys locked box mechanics tied to recent audited financial statements wherever practical. Locked box provisions eliminate post-closing completion account true-ups, prevent accounting policy disputes, and secure pricing certainty at signing.

Mandate Buy-Side W&I Insurance Deployment: Shift operational warranty exposure onto institutional insurers by requiring buyers to secure buy-side W&I insurance. Cap SPA warranty liability at nominal levels (€1 or 0.5% EV) to eliminate cash escrows and protect liquid proceeds at closing.

Structure Objective Earn-Out Covenants: Where earn-outs are necessary to bridge valuation gaps, reject subjective "inward-facing" effort clauses. Anchor payouts to objective regulatory or revenue milestones, mandate binding R&D budget commitments, and insert anti-cannibalization covenants.

Audit Rollover Equity Waterfalls: Evaluate private equity rollover proposals through a rigorous liquidation preference lens. Model how senior debt leverage, sponsor preferred dividend hurdles, and executive option pools impact common equity realization across downside and base-case exit scenarios.

Nelson Advisors > European HealthTech, MedTech, Digital Health Investment Banking

Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Follow Nelson Advisors LinkedIn Page > https://www.linkedin.com/company/nelson-advisors/

Nelson Advisors regularly publish Thought Leadership articles covering market insights, industry trends, deal commentary, market analysis & predictions. https://www.healthcare.digital

Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb

#VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #NelsonAdvisors #HealthTech #MedTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #Canada